7601 Dumbarton Circle
Fremont, CA 94555
United States
510 293 8800
https://www.cymabay.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 101
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Sujal A. Shah | President, CEO & Director | 1.04M | N/A | 1973 |
Dr. Charles A. McWherter Ph.D. | President of Research & Development and Chief Scientific Officer | 700.65k | N/A | 1955 |
Mr. Paul T. Quinlan | General Counsel, Chief Compliance Officer & Corporate Secretary | 629.72k | N/A | 1963 |
Mr. Harish Shantharam C.F.A. | CFO, Principal Accounting & Financial Officer | N/A | N/A | 1982 |
Mr. Ken Boehm | Senior Vice President of Human Resources | N/A | N/A | N/A |
Mr. Patrick J. O'Mara | Senior Vice President of Business Development | N/A | N/A | 1961 |
Dr. Robert L. Martin | Senior Vice President of Manufacturing & Nonclinical Development | N/A | N/A | 1962 |
Ms. Klara A. Dickinson-Eason | Chief Regulatory & Quality Assurance Officer | 441.84k | N/A | 1968 |
Ms. Becki Filice | Senior Vice President of Portfolio & Product Leadership | N/A | N/A | 1961 |
Mr. Ben Kozub | Head of Commercial | N/A | N/A | N/A |
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.
CymaBay Therapeutics, Inc.’s ISS Governance QualityScore as of March 1, 2024 is 6. The pillar scores are Audit: 9; Board: 3; Shareholder Rights: 6; Compensation: 7.